A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

被引:0
|
作者
Godfrey, David A. [1 ]
Peplinski, Lee S. [2 ]
Stewart, Jeanette A. [3 ]
Stewart, William C. [3 ]
机构
[1] Glaucoma Associates Texas, Dallas, TX USA
[2] Kentuckiana Inst Eye Res, Louisville, KY USA
[3] PRN Pharmaceut Res Network LLC, 5001 LBJ Freeway,Suite 700, Dallas, TX 75244 USA
来源
CLINICAL OPHTHALMOLOGY | 2009年 / 3卷
关键词
comfort; travoprost BAK-free; latanoprost; glaucoma; ocular hypertension;
D O I
暂无
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients. Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes. Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0-100 mm) at specified time intervals and a comfort survey. Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 +/- 16.2 mm) and travoprost BAK-free (7.8 +/- 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P +/- 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P +/- 0.05). Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 50 条
  • [31] Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France
    Bernard, LM
    Althin, R
    Dhawan, R
    Grima, DT
    Lam, A
    Aballéa, S
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2003, 13 : S30 - S43
  • [32] Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension
    Franks, Wendy
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (09) : 1643 - 1649
  • [33] Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
    Brant Fernandes, Rodrigo A.
    Silva, Luci Meire P.
    Dias, Diego Torres
    Pereira, Rafael Henrique
    Belfort Jr, Rubens
    Prata, Tiago Santos
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 679 - 684
  • [34] A comparative clinical study of latanoprost and isopropyl unoprostone in Japanese patients with primary open-angle glaucoma and ocular hypertension
    Tsukamoto, H
    Mishima, HK
    Kitazawa, Y
    Araie, M
    Abe, H
    Negi, A
    JOURNAL OF GLAUCOMA, 2002, 11 (06) : 497 - 501
  • [35] Latanoprost versus timolol gel-forming solution once daily in primary open-angle glaucoma or ocular hypertension
    Harasymowycz, Paul
    Hutnik, Cindy M. L.
    Nicolela, Marcelo
    Stewart, William C.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2007, 42 (01): : 75 - 81
  • [36] Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension
    Ge Jian
    Sun Xing-huai
    Wang Ning-li
    Zhao Jia-liang
    Wu Ling-ling
    Chen Xiao-ming
    Wang Zhi-xin
    Li, Benny
    CHINESE MEDICAL JOURNAL, 2010, 123 (11) : 1417 - 1421
  • [37] A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
    Walters, Thomas R.
    Kothe, Angela C.
    Boyer, Jose L.
    Usner, Dale W.
    Lopez, Krisol
    Duquesroix, Brigitte
    Fechtner, Robert D.
    Navratil, Tomas
    JOURNAL OF GLAUCOMA, 2022, 31 (06) : 382 - 391
  • [38] Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension
    Uva, M. G.
    Longo, A.
    Reibaldi, M.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (08) : 1103 - 1109
  • [39] Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension
    M. G. Uva
    A. Longo
    M. Reibaldi
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2009, 247 : 1103 - 1109
  • [40] Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension
    Radell, J. E.
    Serle, J. B.
    DRUGS OF TODAY, 2019, 55 (09) : 563 - 574